L-759,633

Discontinued Product

L-759,633 (Cat. No. 2433) has been withdrawn from sale for commercial reasons.
Cat.No. 2433 - L-759,633 | C26H40O2 | CAS No. 174627-50-0
Description: High affinity, selective CB2 agonist
Chemical Name: (6aR,10aR)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-methoxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for L-759,633

High affinity, selective CB2 receptor agonist (Ki values are 6.4 and 1043 nM for CB2 and CB1 receptors respectively). Potently inhibits forskolin-stimulated cAMP production via CB2 receptors expressed in CHO cells (EC50 = 8.1 nM).

Technical Data for L-759,633

M. Wt 384.59
Formula C26H40O2
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 174627-50-0
PubChem ID 5311215
InChI Key SUFMHSFGODDLKI-NHCUHLMSSA-N
Smiles CCCCCCC(C)(C)C(C=C3OC)=CC2=[C@@]3[C@H]1[C@H]([C@@](C)(C)O2)CC=C(C)C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for L-759,633

References are publications that support the biological activity of the product.

Ross et al (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br.J.Pharmacol. 126 665 PMID: 10188977

Huffman et al (1999) 3-(1',1'-dimethylbutyl)-1-deoxy-D8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg.Med.Chem. 7 2905 PMID: 10658595

Huffman (2000) The search for selective ligands for the CB2 receptor. Curr.Pharmaceut.Des. 6 1323

View Related Products by Target

View Related Products by Product Action

View all CB2 Receptor Agonists

Keywords: L-759,633, L-759,633 supplier, High, affinity, selective, CB2, agonists, cannabinoids, Receptors, cb2r, L759633, 2433, Tocris Bioscience

Citations for L-759,633

Citations are publications that use Tocris products.

Currently there are no citations for L-759,633.

Reviews for L-759,633

There are currently no reviews for this product. Be the first to review L-759,633 and earn rewards!

Have you used L-759,633?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Pain

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Cannabinoid Receptor Ligands

Cannabinoid Receptor Ligands Scientific Review

Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.